Image in cardiology

Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment

EuroIntervention 2013;8:1226-1227 published online ahead of print September 2012. DOI: 10.4244/EIJV8I10A187

Hector Garcia-Garcia
Héctor M. García-García1,2, MD, PhD; Carl Schultz1, MD; Eric Duckers1, MD, PhD; Evelyn Regar1, MD, PhD; Jurgen Ligthart1, BSc; Patrick W. Serruys1, MD, PhD; Robert J. van Geuns1*, MD, PhD
1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Cardialysis BV, Rotterdam, The Netherlands
A 58-year-old man with treated hypercholesterolaemia and a smoking habit was admitted to hospital with stable angina. In April 2006, the patient was treated with an ABSORB bioresorbable everolimus-eluting vascular scaffold system (Abbott Laboratories, Abbott Park, IL, USA) (ABSORB BVS - 3.0×12 mm) in the left circumflex in the context of the ABSORB Cohort A trial. Per protocol, at six-month follow-up and at two years, the patient underwent intravascular imaging. In March 2011, the patient presented with stable angina and in the coronary angiography three intermediate lesions were found and evaluated with fractional flow reserve (FFR); one in the obtuse marginal FFR was 0.79 ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population

Latest news